LIGAND PHARMACEUTICALS INCORPORATED
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $52.0M | $47.1M | $4.9M | $9.0M |
| Jun 2022 | $11.9M | $5.3M | $6.6M | — |
| Sep 2022 | $20.5M | $16.2M | $4.3M | — |
| Mar 2023 | $33.9M | $31.5M | $2.4M | $5.9M |
| Jun 2023 | $-82.0K | $-285.0K | $203.0K | — |
| Sep 2023 | $7.6M | $7.2M | $487.0K | — |
| Mar 2024 | $18.7M | $18.6M | $105.0K | $7.3M |
| Jun 2024 | $13.3M | $12.9M | $408.0K | — |
| Sep 2024 | $36.5M | $35.9M | $596.0K | — |
| Mar 2025 | $-25.4M | $-25.7M | $214.0K | $7.8M |
| Jun 2025 | $15.8M | $15.6M | $214.0K | — |
| Sep 2025 | $13.1M | $13.1M | $15.0K | — |
| Mar 2026 | $48.7M | $48.5M | $228.0K | $10.6M |
| Jun 2026 | $24.0M | $24.0M | $26.0K | — |